Medicine and Dentistry
Neuroendocrine Tumor
100%
Neoplasm
34%
Neuroendocrine Carcinoma
18%
Positron Emission Tomography
17%
Copper 64
15%
Disease
14%
Positron Emission Tomography-Computed Tomography
14%
Somatostatin Receptor
13%
Carcinoid
11%
Surgery
11%
Metastatic Carcinoma
11%
Overall Survival
11%
Radionuclide Therapy
11%
Peptide Receptor
11%
Positron Emission Tomography
10%
Diagnosis
9%
Progression Free Survival
9%
Radioactive Tracer
8%
Gallium 68
7%
Chromogranin A
7%
Cohort Analysis
7%
Primary Tumor
6%
Biological Marker
6%
Pancreas Islet Cell Tumor
6%
Fluorodeoxyglucose F 18
6%
Multiple Endocrine Neoplasia Type I
5%
Recurrent Disease
5%
Fluorine-18
5%
Liver Metastasis
5%
Gastroenteropancreatic Neuroendocrine Tumor
5%
Lutetium 177
5%
Etoposide
5%
Symptom
5%
Prognostic Factor
5%
Keyphrases
Neuroendocrine Tumor
45%
Neuroendocrine Neoplasms
33%
64Cu-DOTATATE
14%
Tumor
13%
Neuroendocrine Carcinoma
13%
Positron Emission Tomography-computed Tomography (PET-CT)
12%
Overall Survival
11%
Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
11%
Histamine
11%
Peptide Receptor Radionuclide Therapy
11%
Ki-67 Index
10%
Chromogranin A
10%
DOTATATE PET
10%
Pancreatic Neuroendocrine Tumors (pNETs)
9%
Small Intestinal Neuroendocrine Tumors
8%
Head-to-head Comparison
8%
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
8%
Ki-67
8%
Progression-free Survival
8%
Gallium-68
7%
DOTATATE
6%
Stress-induced
6%
Pancreas
6%
Copenhagen
6%
Metastasis
5%
Arginine Vasopressin
5%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
5%
Vasopressin
5%
Multiple Endocrine Neoplasia Type 1 (MEN1)
5%
Somatostatin Receptor Imaging
5%
Primary Tumor
5%
Prognostic Factors
5%
Positron Emission Tomography
5%
Tumor Patients
5%
